Table 1 Demographics and co-morbidities (N = 25)
From: “Life-changing”: the experience of super-responders to biologics in severe asthma
n (%) | ||
|---|---|---|
Biologic | Omalizumab | 2 (8) |
Mepolizumab | 7 (28) | |
Benralizumab | 15 (60) | |
Dupilumab | 1 (4) | |
Gender and age | Male | 9 (36) |
Age 18–34 | 1 | |
35–49 | 1 | |
50–64 | 3 | |
65–79 | 4 | |
Female | 16 (64) | |
Age 18–34 | 2 | |
35–49 | 3 | |
50–64 | 7 | |
65–79 | 4 | |
Ethnicity | Caucasian | 24 (96) |
Mixed race | 1 (4) | |
Age at onset | Adult | 17 (68) |
Child | 8 (32) | |
Smoking | Never | 17 (68) |
Ex | 8 (32) | |
Current | 0 | |
Nasal polyps | Present 7 (28) | |
Absent 18 (72) | ||
Mean (range) | ||
Age | 56 (56–77) | |
BMI (Kg/m2) | 29.6 (21–47) | |
Maximum Eosinophils in 12 months preceding biologic | 0.78 (0.2–1.48) | |
Months since initiation# | 22 (7–44) | |